Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Tarih
2021
Yazar
Oral, Elif A.
Akinci, Baris
Subauste, Angela
Ajluni, Nevin
Esfandiari, Nazanene H.
Meral, Rasimcan
Neidert, Adam H.
Burant, Charles L.
Eraslan, Akin
Hench, Rita
Rus, Diana
Mckenna, Barbara
Hussain, Hero K.
Chenevert, Thomas L.
Tayeh, Marwan K.
Rupani, Amit R.
Innis, Jeffrey W.
Mantzoros, Christos S.
Conjeevaram, Hari S.
Üst veri
Tüm öğe kaydını göster
Özet
Background: Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve NASH in more common forms of this heterogeneous condition.
Bağlantı
http://hdl.handle.net/20.500.12627/176264
https://doi.org/10.1016/j.medj.2021.04.001
Koleksiyonlar